Skip to main content

Table 2 Specialties of providers primarily prescribing and managing systemic bevacizumab for HHT-related HOCF in HHT centers

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

SpecialtyPercent of Centers
Hematology50%
Pulmonology39%
Cardiology11%
Gastroenterology6%
Internal Medicine6%